Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
33%(2 trials)

Phase Distribution

Ph phase_3
2
33%
Ph phase_1
2
33%
Ph phase_2
2
33%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_3

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02242487
completedphase_1

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

NCT03887884
completedphase_3

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

NCT02352363
completedphase_2

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

NCT01777555
completedphase_2

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

NCT01617135
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02242487Phase 3

Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

Completed
NCT03887884Phase 1

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Completed
NCT02352363Phase 3

Randomized Safety Study of CVT-301 Compared to an Observational Control Group

Completed
NCT01777555Phase 2

Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes

Completed
NCT01617135Phase 2

Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes

Completed
NCT02633839Phase 1

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6